Image Courtesy : www.pgimsrohtak.ac.in

The human clinical trial for Phase-II has begun for the indigenous COVID-19 vaccine, Covaxin, by PGIMS (Post Graduate Institute of Medical Sciences), Rohtak. The trials will be regulated on 380 volunteers across the country out of which 50 will be regulated at PGIMS, Rohtak.

The trial for the first dose of Covaxin, the COVID vaccine, which was developed by Bharat Biotech in partnership with NIV (National Institute of Virology) and ICMR (Indian Council of Medical Research), had been volunteered by 12 volunteers aged from 12 years to 65 years.

As per the reports, the volunteers were supervised for the first dose of 03 microgram whereas the young males have been discharged with 06 microgram dosage of the vaccine. The volunteers were kept for 02 days under observation and the positive results were shown but not all volunteers were healthy that's why the second trial will consist of two dosages and the volunteers will be kept under observation for 28 days.

The second trial has already been started, as reported by the co-examiner of the trials at PGIMS, Dr. Ramesh Verma.